Latest & greatest articles for donepezil

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on donepezil or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on donepezil and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for donepezil

41. Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease

Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer’s disease Article Text Therapeutics Donepezil improves cognitive function and reduces decline in activities of daily living

Evidence-Based Mental Health2006

42. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. 16581404 2006 04 03 2006 04 13 2015 06 16 1474-547X 367 9516 2006 Apr 01 Lancet (London, England) Lancet Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. 1057-65 The cholinesterase inhibitor donepezil is used to treat mild-to-moderate Alzheimer's disease. Its efficacy in severe dementia has not been assessed (...) and is controversial. Our aim was to ascertain the effectiveness of donepezil in patients with severe Alzheimer's disease, by focusing primarily on cognition and activities of daily living. We did a 6-month, double-blind, parallel-group, placebo-controlled study in 248 patients with severe Alzheimer's disease (mini mental state examination score 1-10) who were living in assisted care nursing homes ran by trained staff in Sweden. We assigned patients oral donepezil (5 mg per day for 30 days then up to 10 mg per day

Lancet2006

43. Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease

Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate Alzheimer’s disease Article Text Therapeutics Donepezil did not reduce the rate of institutionalisation or disability in people with mild to moderate

Evidence-Based Mental Health2005

44. Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease

Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Article Text Therapeutics Donepezil is more effective than galantamine for mild to moderate Alzheimer’s disease Free James Warner , MD, MRCP, MRCPsych Statistics from Altmetric.com No Altmetric data available for this article. Jones RW

Evidence-Based Mental Health2005

45. Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease

Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Article Text Therapeutics Memantine plus donepezil improves physical and mental health in people with Alzheimer’s disease Free Rupert H McShane , MD, MRCPsych Statistics from Altmetric.com No Altmetric data

Evidence-Based Mental Health2005

46. Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden

Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Donepezil slows decline in daily life activities in people with moderate to severe Alzheimer’s disease and alleviates caregiver burden Article Text Therapeutics Donepezil slows decline in daily life activities in people with moderate

Evidence-Based Mental Health2005

47. A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis

A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease: a meta-analysis Harry R D, Zakzanis K K CRD summary This review compared donepezil and galantamine separately with placebo. The authors concluded (...) that the drugs have limited effects on measures of cognitive ability, and that galantamine is not superior to donepezil. The first conclusion should be treated with caution because of methodological limitations in the review, while the second could not be reliably obtained by considering only placebo-controlled trials. Authors' objectives To evaluate the efficacy of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer's disease (AD). A stated secondary objective was to determine

DARE.2005

48. Vitamin E and donepezil for the treatment of mild cognitive impairment.

Vitamin E and donepezil for the treatment of mild cognitive impairment. 15829527 2005 06 09 2005 06 16 2016 12 08 1533-4406 352 23 2005 Jun 09 The New England journal of medicine N. Engl. J. Med. Vitamin E and donepezil for the treatment of mild cognitive impairment. 2379-88 Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease. In a double-blind study, we evaluated subjects with the amnestic subtype of mild cognitive (...) impairment. Subjects were randomly assigned to receive 2000 IU of vitamin E daily, 10 mg of donepezil daily, or placebo for three years. The primary outcome was clinically possible or probable Alzheimer's disease; secondary outcomes were cognition and function. A total of 769 subjects were enrolled, and possible or probable Alzheimer's disease developed in 212. The overall rate of progression from mild cognitive impairment to Alzheimer's disease was 16 percent per year. As compared with the placebo group

NEJM2005

49. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, Edwards S, Hardyman W, Raftery J, Crome P, Lendon C, Shaw H, Bentham P Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of donepezil (5 or 10 mg/day) for the treatment of patients with Alzheimer's disease. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population

NHS Economic Evaluation Database.2004

50. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. 15220031 2004 06 28 2004 07 13 2016 12 08 1474-547X 363 9427 2004 Jun 26 Lancet (London, England) Lancet Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. 2105-15 Cholinesterase inhibitors produce small improvements in cognitive and global assessments in Alzheimer's disease. We aimed to determine whether donepezil produces (...) worthwhile improvements in disability, dependency, behavioural and psychological symptoms, carers' psychological wellbeing, or delay in institutionalisation. If so, which patients benefit, from what dose, and for how long? 565 community-resident patients with mild to moderate Alzheimer's disease entered a 12-week run-in period in which they were randomly allocated donepezil (5 mg/day) or placebo. 486 who completed this period were rerandomised to either donepezil (5 or 10 mg/day) or placebo, with double

Lancet2004

51. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. 14734594 2004 01 21 2004 01 29 2016 12 08 1538-3598 291 3 2004 Jan 21 JAMA JAMA Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. 317-24 Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist. Controlled trials have demonstrated the safety (...) and efficacy of memantine monotherapy for patients with moderate to severe Alzheimer disease (AD) but no controlled trials of memantine in patients receiving a cholinesterase inhibitor have been performed. To compare the efficacy and safety of memantine vs placebo in patients with moderate to severe AD already receiving stable treatment with donepezil. A randomized, double-blind, placebo-controlled clinical trial of 404 patients with moderate to severe AD and Mini-Mental State Examination scores of 5 to 14

JAMA2004

52. The value of the managed entry of new drugs: a case study of donepezil

The value of the managed entry of new drugs: a case study of donepezil The value of the managed entry of new drugs: a case study of donepezil The value of the managed entry of new drugs: a case study of donepezil Payne K, Davies L M, Noyce P R, Weiss M C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Three models to manage the entry of new drugs (in the case, donepezil) into practice were examined. In model 1, the Health Authority managed the entry of donepezil by using existing services with consultant assessment and general practitioners (GPs) taking up prescribing after 5 weeks. In model 2, the Health Authority managed the entry of donepezil by using existing services with consultant-only prescribing. In model 3, the Health

NHS Economic Evaluation Database.2003

53. Donepezil for dementia due to Alzheimer's disease.

Donepezil for dementia due to Alzheimer's disease. BACKGROUND: Alzheimer's disease is the most common cause of dementia in older people. One of the aims of therapy is to inhibit the breakdown of a chemical neurotransmitter, acetylcholine, by blocking the relevant enzyme. This can be done by a group of chemicals known as cholinesterase inhibitors. However, some (like tacrine) are associated with adverse effects such as hepatotoxicity, but donepezil (E2020, Aricept) is safer. OBJECTIVES (...) : The objective of this review is to assess whether donepezil improves the well-being of patients with dementia due to Alzheimer's disease. SEARCH STRATEGY: The Cochrane Dementia and Cognitive Improvement Group's Specialized Register was searched using the terms 'donepezil', 'E2020' and 'Aricept' on 9 October 2002. This Register contains up-to-date records of all major health care databases and many ongoing trial databases. Members of the Donepezil Study Group and Eisai Inc were contacted. SELECTION CRITERIA

Cochrane2003

54. Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost effectiveness Wolfson C, Oremus M, Shukla (...) V, Momoli F, Demers L, Perrault A, Moride Y Authors' objectives To assess the efficacy and safety of donepezil and rivastigmine in the treatment of Alzheimer's disease (AD). Searching MEDLINE, HealthSTAR and PsycINFO were searched from January 1984 to May 2000; the key terms were stated. Unpublished studies and abstracts were excluded. The reference lists in identified studies were handsearched. The search was updated by searching the same databases from May 2000 to October 2001. Study selection

DARE.2002

55. Economic evaluation of donepezil treatment for Alzheimer's disease in Japan

Economic evaluation of donepezil treatment for Alzheimer's disease in Japan Economic evaluation of donepezil treatment for Alzheimer's disease in Japan Economic evaluation of donepezil treatment for Alzheimer's disease in Japan Ikeda S, Yamada Y, Ikegami N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The use of donepezil (Aricept) for the treatment of mild and moderate Alzheimer's disease (AD). Patients were assumed to receive donepezil at 3 mg/day for 1 week after the start of treatment and at 5 mg/day thereafter. The comparator was standard therapy. Type of intervention Secondary prevention and palliative care. Economic study type Cost-utility analysis. Study population The study population comprised patients

NHS Economic Evaluation Database.2002

56. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia

Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia Fajemisin B Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Fajemisin B. Acetylcholinesterase inhibitors: donepezil, rivastigmine, tacrine or galantamine for non-Alzheimer's dementia. London: Bazian Ltd (Editors), Wessex Institute for Health Research and Development, University of Southampton 2002: 9 Authors' objectives This study aims to assess the effects of acetylcholinesterase inhibitors (donepezil, rivastigmine, tacrine, galantamine) on functional outcomes in people with non-Alzheimer's dementia. Authors' conclusions We found

Health Technology Assessment (HTA) Database.2002

57. Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N Authors' objectives To provide a rapid (...) and systematic review of the clinical effectiveness and cost-effectiveness of donepezil, rivastigmine and galantamine in the symptomatic treatment of people suffering from Alzheimer's disease (AD). Searching The following databases were searched from their inception to March to July, 2000: MEDLINE, EMBASE, the Cochrane Library, DARE, NHS EED, the National Researh Register, the Science Citation Index, BIOSIS Previews, EconLit, the MRC Clinical Trials Directory, an Early Warning System database, Current

DARE.2001

58. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease

Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 19. 2001 Authors' objectives To provide guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. Authors' conclusions Guidance 1.1 The three drugs donepezil, rivastigmine

Health Technology Assessment (HTA) Database.2001

59. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimers disease: a rapid and systematic review. Health Technology Assessment 2001; 5(1): 1-137 Authors' objectives To provide a rapid and systematic review of the clinical

Health Technology Assessment (HTA) Database.2001

60. Donepezil: a review of its use in Alzheimer's disease

Donepezil: a review of its use in Alzheimer's disease Donepezil: a review of its use in Alzheimer's disease Donepezil: a review of its use in Alzheimer's disease Dooley M, Lamb H M Authors' objectives To review the use of donepezil in Alzheimer's disease. Searching AdisBase (a proprietary database of Adis International, Auckland, New Zealand) and MEDLINE were searched from 1966 using the terms 'donepezil' or 'E-2020'. Searches were last updated 12 Jan 2000 and there were no language (...) preferred. Specific interventions included in the review Donepezil compared with placebo. In four of the included studies, patients received oral donepezil 1 to 10mg once daily for 12 to 24 weeks followed by a 2- to 6-week single-blind placebo-wash-out period. In those patients receiving 10mg per day, treatment was initiated with the 5mg dosage and increased, after one week, to 10mg. In a further three Japanese studies, two short-term trials (8 or 12 weeks duration) compared donepezil 2mg with 0.1mg

DARE.2000